The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Sunday, 22 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor UK News

How Does Daraxonrasib Work Against Pancreatic Cancer?

By The Daily Byte ·21 Nov 2026 ·7 min read
A cancer research laboratory

A once-a-day pill for advanced pancreatic cancer has made tumours undetectable on scans in one in 12 patients, according to new trial results presented on Friday, 20 November, at the EORTC-NCI-AACR cancer symposium in Barcelona. The drug, daraxonrasib, was given alongside chemotherapy to 61 people newly diagnosed with pancreatic cancer that had already spread. In 8.2 per cent of them, the cancer could no longer be seen on scans, tumours shrank or disappeared in 60.7 per cent, and the disease stopped growing in 90.2 per cent. After a year, 76.6 per cent of patients were still alive, compared with around 40 to 45 per cent of patients given chemotherapy alone. Doctors presenting the results called it the closest thing to a cure they had seen in this disease — but they also stressed that the study was small and early. So how does daraxonrasib actually work?

What is daraxonrasib?

Daraxonrasib is a first-in-class oral drug, also known by its development code RMC-6236, developed by the American company Revolution Medicines with the Dana-Farber Cancer Institute. It is a pan-RAS inhibitor, meaning it targets the whole RAS family of proteins — KRAS, NRAS and HRAS — rather than a single mutant form. In the new study, known as RMC-GI-102, patients took a 200 mg tablet once a day alongside two standard chemotherapy drugs, gemcitabine and nab-paclitaxel, given by infusion. The trial was a phase 1/2 study, the early stage of testing in people, and patients were followed for a median of 18 months.

The drug is already approved in the United States. The Food and Drug Administration approved it on 26 August 2026, under the brand name Rasonque, for adults with metastatic pancreatic cancer who have already had at least one prior treatment, or who cannot have multi-drug chemotherapy. The European Union approved it on 18 November 2026. But the new Barcelona results are different: they test daraxonrasib as a first treatment, combined with chemotherapy, in people whose cancer has just been diagnosed.

How does it work? The molecular glue

Daraxonrasib works through an unusual mechanism that scientists describe as a "molecular glue". Rather than docking into a pocket on the RAS protein itself, the small molecule first binds to cyclophilin A, a common protein inside cells that does not normally interact with RAS. That drug-cyclophilin pair is then captured by RAS in its active, GTP-bound form, assembling a three-part complex that physically blocks the proteins RAS normally signals through, such as RAF, from docking onto it. In effect, the drug borrows a bystander protein and glues it onto the cancer's growth switch, jamming it in the off position.

The design also gives the drug a second trick. Structural studies show the three-part complex positions chemical groups in a way that actively promotes the breakdown of GTP, the fuel molecule that keeps RAS switched on, restoring some of the protein's own off-switch function. This matters because the mutations that drive pancreatic cancer lock RAS in its active, GTP-loaded state, so simply trapping the protein is not enough — the drug also helps drain the active pool.

Why KRAS was called undruggable

RAS proteins act like switches that tell cells when to grow. In healthy cells they flip between an inactive state, bound to a molecule called GDP, and an active state, bound to GTP. Mutations at three spots in the gene — codons 12, 13 and 61 — break the off-switch, leaving RAS permanently active and driving relentless cell growth through the RAF-MEK-ERK, PI3K-AKT-mTOR and RALGDS pathways. KRAS is mutated in more than 90 per cent of pancreatic tumours, and it is the most frequently mutated driver gene in human cancer.

For decades KRAS was considered "undruggable". The protein's surface offers no obvious pocket for a drug to grip, and it binds its GTP fuel with extraordinary tightness. The first KRAS drugs, approved in recent years, only worked against one specific mutation, G12C, which is rare in pancreatic cancer. Daraxonrasib sidesteps the problem entirely: by binding cyclophilin A first and then the active form of RAS, it can block many different RAS variants — the common G12, G13 and Q61 mutants as well as the normal, unmutated protein — which is why it is called a pan-RAS inhibitor. Cancer cells carrying mutant RAS hold a much larger share of their RAS in the active, GTP-bound state than healthy cells do, so the drug preferentially shuts down the tumour's signalling while sparing normal tissue.

What the earlier phase 3 trial showed

The new combination results build on a larger, randomised phase 3 trial, RASolute 302, whose results were presented at the American Society of Clinical Oncology annual meeting in 2026 and published in the New England Journal of Medicine. That trial tested daraxonrasib on its own, as a second treatment, in people with previously treated metastatic pancreatic cancer. Median overall survival was 13.2 months with daraxonrasib, compared with 6.7 months with chemotherapy chosen by the patient's doctor — nearly double, with a hazard ratio of 0.40, meaning the risk of death was cut by 60 per cent. Tumours shrank in about 30 per cent of patients on the drug, against about 11 per cent on chemotherapy, and side effects were broadly similar, with severe adverse events in 61.8 per cent of patients on daraxonrasib and 69.6 per cent on chemotherapy. Rash and diarrhoea were the most common side effects.

Those results were the first time a drug directly targeting RAS had doubled survival in pancreatic cancer, and they are the basis for the drug's approval. The new Barcelona study asks a different question: what happens when the drug is added to chemotherapy from the start, before the cancer has been treated at all? On the early evidence, the combination looks stronger still — a response rate of 60.7 per cent, a disease control rate of 90.2 per cent, and an average of 12.8 months before tumours started growing again.

What the new results do not prove

The excitement comes with important caveats, and the researchers and independent experts have been careful to state them. The Barcelona study involved only 61 patients, it had no randomised control group, and the comparisons with chemotherapy alone are against historical figures, not against patients treated in the same trial. As Professor Shivan Sivakumar of the University of Birmingham put it, those comparisons are "not definitive, and we do not yet know whether these promising results will translate into longer overall survival".

Nor is the drug a cure. Dr Wungki Park, the gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York who presented the findings, said the results were "the closest to cure" he had seen, but doctors do not yet know how long the benefits last, whether resistance will develop, or how long patients can stay on the treatment. Pancreatic Cancer UK's head of research, Dr Madina Kara, called it "a small, initial study" while welcoming the results, and Cancer Research UK noted that the drug had found "a way of drugging the undruggable".

What happens next

Daraxonrasib is now being tested in four global phase 3 trials — three in pancreatic cancer and one in non-small cell lung cancer. The most important is RASolute 303, an international trial testing the daraxonrasib-and-chemotherapy combination against standard chemotherapy in newly diagnosed patients, which will determine whether the Barcelona results genuinely improve survival. The final phase 3 study in the United States already has enough patients, although some sites in Europe may still have places.

The context is a disease with some of the worst survival figures in cancer. Only around 25 per cent of adults diagnosed with pancreatic cancer survive for longer than a year, according to Cancer Research UK, and half of people with the disease die within three months of diagnosis. Against that background, a pill that made tumours vanish in one in 12 patients in its first test, and kept the disease in check in nine in 10, is a genuine breakthrough — but one whose promise now has to survive the much harder test of a large randomised trial.